Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19).
作者信息
Pallotto Carlo, Blanc Pierluigi, Esperti Sara, Suardi Lorenzo Roberto, Gabbuti Andrea, Vichi Francesca, Mecocci Lorenzo, Esposti Anna Degli, Pierotti Piera, Attala Letizia, Salomoni Elena, Baragli Filippo, Francisci Daniela, Pietro Massimo Antonio Di
机构信息
Infectious Diseases Unit 1, Santa Maria Annunziata Hospital, Azienda USL Toscana Centro, via Antella, 56, Bagno a Ripoli, Florence, Italy; Infectious Diseases Clinic, Santa Maria della Misericordia University Hospital, University of Perugia, Piazzale Gambuli, 1, Perugia, Italy.
Infectious Diseases Unit 1, Santa Maria Annunziata Hospital, Azienda USL Toscana Centro, via Antella, 56, Bagno a Ripoli, Florence, Italy; Infectious Diseases Unit 2, San Jacopo Hospital, Azienda USL Toscana Centro, via Ciliegiole, 97, Pistoia, Italy.
出版信息
J Infect. 2021 Aug;83(2):237-279. doi: 10.1016/j.jinf.2021.05.025. Epub 2021 May 28.
Abstract
摘要
相似文献
1
Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19).瑞德西韦治疗2019冠状病毒病（COVID-19）患者与短暂性心动过缓
J Infect. 2021 Aug;83(2):237-279. doi: 10.1016/j.jinf.2021.05.025. Epub 2021 May 28.
2
Sinus Bradycardia in a Pediatric Patient Treated With Remdesivir for Acute Coronavirus Disease 2019: A Case Report and a Review of the Literature.瑞德西韦治疗儿童急性 2019 冠状病毒病合并窦性心动过缓：病例报告及文献复习。
J Pediatric Infect Dis Soc. 2021 Oct 27;10(9):926-929. doi: 10.1093/jpids/piab029.
3
Remdesivir might induce changes in electrocardiogram beyond bradycardia in patients with coronavirus disease 2019-The pilot study.瑞德西韦可能会使2019冠状病毒病患者的心电图出现除心动过缓之外的变化——一项初步研究。
J Med Virol. 2021 Oct;93(10):5724-5725. doi: 10.1002/jmv.27177. Epub 2021 Jul 14.
4
Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19).2019冠状病毒病（COVID-19）患者中与瑞德西韦相关的潜在短暂性心动过缓
J Med Virol. 2021 May;93(5):2631-2634. doi: 10.1002/jmv.26898. Epub 2021 Mar 3.
5
Sinus Bradycardia in Children Treated With Remdesivir for COVID-19.使用瑞德西韦治疗新冠病毒病的儿童出现窦性心动过缓
Pediatr Infect Dis J. 2021 Sep 1;40(9):e356. doi: 10.1097/INF.0000000000003214.
6
Severe sinus bradycardia associated with remdesivir in a child with severe SARS-COV-2 infection-reply.一名患有严重SARS-CoV-2感染的儿童使用瑞德西韦后出现严重窦性心动过缓——回复
Eur J Pediatr. 2021 May;180(5):1629-1630. doi: 10.1007/s00431-021-03952-0. Epub 2021 Jan 19.
7
Remdesivir therapy associated with Bradycardia in SARS-CoV2.瑞德西韦治疗与新型冠状病毒肺炎患者心动过缓有关。
Clin Cardiol. 2021 Sep;44(9):1190-1191. doi: 10.1002/clc.23700. Epub 2021 Jul 28.
8
Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection.一名患有严重新型冠状病毒 2 型（SARS-CoV-2）感染的儿童使用瑞德西韦后出现严重窦性心动过缓。
Eur J Pediatr. 2021 May;180(5):1627. doi: 10.1007/s00431-021-03940-4. Epub 2021 Jan 23.
9
Remdesivir, Sinus Bradycardia and Therapeutic Drug Monitoring in Children With Severe COVID-19.瑞德西韦、窦性心动过缓与重症新型冠状病毒肺炎儿童的治疗药物监测
Pediatr Infect Dis J. 2021 Dec 1;40(12):e528-e529. doi: 10.1097/INF.0000000000003309.
10
Remdesivir-associated bradycardia.瑞德西韦相关心动过缓。
BMJ Case Rep. 2021 Sep 3;14(9):e245289. doi: 10.1136/bcr-2021-245289.
引用本文的文献
1
Incidence of bradycardia with the use of remdesivir for coronavirus disease of 2019 and risk factor analysis.使用瑞德西韦治疗2019冠状病毒病时心动过缓的发生率及危险因素分析。
Int J Crit Illn Inj Sci. 2024 Oct-Dec;14(4):203-207. doi: 10.4103/ijciis.ijciis_57_24. Epub 2024 Dec 23.
2
Maxillary Mucormycotic Osteonecrosis as a Manifestation of Post-COVID-19 Infection in Non-diabetic Patients: Report of Two Cases.非糖尿病患者中作为新冠感染后表现的上颌毛霉病性骨坏死：两例报告
J Microsc Ultrastruct. 2023 Nov 2;12(2):99-103. doi: 10.4103/jmau.jmau_81_23. eCollection 2024 Apr-Jun.
3
Remdesivir-Induced Bradycardia and Mortality in SARS-CoV-2 Infection, Potential Risk Factors Assessment: A Systematic Review and Meta-Analysis.瑞德西韦在新冠病毒感染中导致的心动过缓和死亡率：潜在风险因素评估——一项系统评价与荟萃分析
J Clin Med. 2023 Dec 5;12(24):7518. doi: 10.3390/jcm12247518.
4
Remdesivir treatment and clinical outcome in non-severe hospitalized COVID-19 patients: a propensity score matching multicenter Italian hospital experience.瑞德西韦治疗非重症住院 COVID-19 患者的疗效和临床结局：一项倾向评分匹配的多中心意大利医院经验。
Eur J Clin Pharmacol. 2023 Jul;79(7):967-974. doi: 10.1007/s00228-023-03499-z. Epub 2023 May 22.
5
Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study.新冠住院患者中瑞德西韦相关心动过缓的发生率及潜在危险因素：一项回顾性队列研究。
Front Pharmacol. 2023 Feb 1;14:1106044. doi: 10.3389/fphar.2023.1106044. eCollection 2023.
6
Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study.瑞德西韦与新型冠状病毒肺炎患者窦性心动过缓的相关性：一项前瞻性纵向研究。
Front Pharmacol. 2023 Jan 17;13:1107198. doi: 10.3389/fphar.2022.1107198. eCollection 2022.
7
Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism.瑞德西韦在住院治疗 SARS-CoV2 感染患者中引起的心动过缓：一种可能的迷走神经介导机制。
Intern Emerg Med. 2023 Mar;18(2):359-366. doi: 10.1007/s11739-022-03168-6. Epub 2022 Dec 21.
8
Permanent Pacemaker Placement Secondary to Remdesivir Induced Bradycardia: A Case Report.瑞德西韦诱导的心动过缓继发永久性起搏器植入：一例报告
Cureus. 2022 Oct 31;14(10):e30923. doi: 10.7759/cureus.30923. eCollection 2022 Oct.
9
Remdesivir for patients with Coronavirus disease 2019 pneumonia requiring high oxygen support.瑞德西韦用于治疗需要高流量吸氧支持的2019冠状病毒病肺炎患者。
Qatar Med J. 2022 Jun 16;2022(3):25. doi: 10.5339/qmj.2022.25. eCollection 2022.
10
Remdesivir-induced Bradycardia is not Associated with Worse Outcome in Patients with COVID-19: A Retrospective Analysis.瑞德西韦引起的心动过缓与 COVID-19 患者的不良结局无关：一项回顾性分析。
Am J Cardiovasc Drugs. 2022 Nov;22(6):705-710. doi: 10.1007/s40256-022-00547-4. Epub 2022 Aug 25.
本文引用的文献
1
Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review.瑞德西韦治疗新型冠状病毒肺炎相关窦性心动过缓：一例报告及文献综述
J Cardiovasc Dev Dis. 2021 Feb 12;8(2):18. doi: 10.3390/jcdd8020018.
2
Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.严重心动过缓和瑞德西韦治疗2019冠状病毒病（COVID-19）：一个新的安全问题。
Clin Microbiol Infect. 2021 Feb 27;27(5):791.e5-8. doi: 10.1016/j.cmi.2021.02.013.
3
Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19).2019冠状病毒病（COVID-19）患者中与瑞德西韦相关的潜在短暂性心动过缓
J Med Virol. 2021 May;93(5):2631-2634. doi: 10.1002/jmv.26898. Epub 2021 Mar 3.
4
Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review.瑞德西韦治疗新型冠状病毒肺炎相关的显著窦性心动过缓：1例病例及文献综述
JACC Case Rep. 2020 Nov 18;2(14):2260-2264. doi: 10.1016/j.jaccas.2020.08.025. Epub 2020 Oct 28.
5
Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19.瑞德西韦用于新冠肺炎患者临床试验中不良事件报告的质量
Eur J Clin Pharmacol. 2021 Mar;77(3):435-437. doi: 10.1007/s00228-020-03008-6. Epub 2020 Oct 4.
6
Risk factors for non-invasive/invasive ventilatory support in patients with COVID-19 pneumonia: A retrospective study within a multidisciplinary approach.COVID-19 肺炎患者接受无创/有创通气支持的风险因素：多学科方法的回顾性研究。
Int J Infect Dis. 2020 Nov;100:258-263. doi: 10.1016/j.ijid.2020.09.012. Epub 2020 Sep 11.
7
Clinical characteristics of COVID-19 patients with complication of cardiac arrhythmia.新型冠状病毒肺炎合并心律失常患者的临床特征
J Infect. 2020 Sep;81(3):e6-e8. doi: 10.1016/j.jinf.2020.07.012. Epub 2020 Jul 11.
8
Increased CD4/CD8 ratio as a risk factor for critical illness in coronavirus disease 2019 (COVID-19): a retrospective multicentre study.2019冠状病毒病（COVID-19）中CD4/CD8比值升高作为危重症风险因素的回顾性多中心研究
Infect Dis (Lond). 2020 Sep;52(9):675-677. doi: 10.1080/23744235.2020.1778178. Epub 2020 Jun 16.
9
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.美国传染病学会关于2019冠状病毒病患者治疗与管理的指南
Clin Infect Dis. 2020 Apr 27. doi: 10.1093/cid/ciaa478.
10
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.瑞德西韦是一种直接作用的抗病毒药物，能高效抑制严重急性呼吸综合征冠状病毒 2 的 RNA 依赖性 RNA 聚合酶。
J Biol Chem. 2020 May 15;295(20):6785-6797. doi: 10.1074/jbc.RA120.013679. Epub 2020 Apr 13.
Zotero 插件